Manufacturer
3 recalls in our database name ImprimisRx NJ as the manufacturing or recalling firm.
Of the 3 recalls from ImprimisRx NJ we have scored against our rubric, 0 (0%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 1 (33%) are Severe.
The manufacturer string comes from the agency’s own source notice — for FDA recalls, the “recalling firm” field; for NHTSA recalls, the vehicle manufacturer; for CPSC recalls, the firm-of-record on the joint press release. A single corporate family can appear under multiple manufacturer strings as agency notices aren’t standardized on a canonical name. If you don’t see recalls you expect, try a parent-company search or a broader full-text search.
Severity scores below are computed from the agency’s classification and the recall text, never from manufacturer behaviour or history. Many manufacturers issue routine corrective actions (software updates, labelling corrections) that are correctly scored low — having recalls on this list isn’t inherently a quality signal.
ImprimisRx is recalling 960 bottles of compounded Timolol-Latanoprost ophthalmic drops nationwide. Affected batches contain less than 90% of the labeled latanoprost amount.
ImprimisRx NJ is recalling 246 bottles of Timolol-Dorzolamide-Latanoprost ophthalmic drops because the medication was found to be subpotent.
ImprimisRx NJ is voluntarily recalling 405 bottles of Timolol-Latanoprost P-F ophthalmic drops because the medication was found to be subpotent.